Xenon to present long-term Azetukalner results and lead patient-provider symposium at AES 2025

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting (AES 2025), taking place December 5-9, 2025 at the Georgia World Congress Center in Atlanta, Georgia. Seven posters will be presented, including new long-term data from the ongoing X-TOLE open-label extension study of azetukalner in patients with focal onset seizures (FOS), and data characterizing patterns of seizure freedom epochs with extended use of azetukalner, which could inform future clinical practice. Xenon’s poster presentations also include findings on the impact of depression on epilepsy patients, as well as new pre-clinical data from the Company’s early-stage Na_V1.1 program in Dravet syndrome.

Long-Term Data for Azetukalner in Epilepsy

• Poster Presentation #1.377: Characterization of Long-Term Seizure Freedom in the Ongoing Open-Label Extension of X-TOLE: Potential Implications for Future Clinical Practice
  Author Session: Saturday, December 6 from 12:00 – 2:00 pm ET in Exhibit Hall B2, Poster Session 1

• Poster Presentation #3.356: Long-Term Safety and Efficacy of Azetukalner, a Novel, Potent KV7 Potassium Channel Opener, in Adults with Focal Epilepsy: ≥48-Month Interim Analysis of the Ongoing 7-Year X-TOLE Open-Label Extension
  Author Session: Monday, December 8 from 12:00 – 1:45 pm ET in Poster Hall B3, Poster Session 3

Epilepsy Real World Studies

• Poster Presentation #1.364: Depression Symptom Experience Among Patients with Epilepsy Reporting a Diagnosis of Focal Seizures (FS): A Patient-Reported Outcomes Study
  Author Session: Saturday, December 6 from 12:00 – 2:00 pm ET in Exhibit Hall B2, Poster Session 1

• Poster Presentation #1.365: Impact of Depression on Outcomes and Treatment Patterns in Patients with Newly Diagnosed Epilepsy: A Retrospective Claims Analysis
  Author Session: Saturday, December 6 from 12:00 – 2:00 pm ET in Exhibit Hall B2, Poster Session 1

• Poster Presentation #2.325: Multivariable Models Reporting Increased Economic and Humanistic Burden Among Patients With Epilepsy Reporting Focal Seizures (FS) Experiencing Moderate to Severe Depression Symptoms
  Author Session: Sunday, December 7 from 12:00 – 2:00 pm ET in Exhibit Hall B2, Poster Session 2

• Poster Presentation #2.367: Clinical Practice and Patient Burden Associated with Anti-Seizure Medication Titration: A Thematic Analysis
  Author Session: Sunday, December 7 from 12:00 – 2:00 pm ET in Exhibit Hall B2, Poster Session 2

Early-stage Pipeline Data

• Poster Presentation #3.181: Selective Potentiation of NaV1.1 Channels in Dravet Mice Suppresses Spontaneous Seizures, Prevents SUDEP and Increases Long Term Potentiation
  Author Session: Monday, December 8 from 12:00 – 1:45 pm ET in Poster Hall B3, Poster Session 3

Satellite Symposium
Xenon is hosting a symposium in partnership with the Epilepsy Foundation of America (EFA) entitled “Exploring Depression and Anxiety in Epilepsy: A Practical Dialogue with Patients and Providers” on Saturday, December 6, 2025 from 6:00 – 9:00 pm ET in Room B213. The panel presentation will feature several representatives from EFA, as well as Dr. Jacqueline A. French, epileptologist and neurologist with the NYU Langone Comprehensive Epilepsy Center, Dr. Andres M. Kanner, Professor of Clinical Neurology and Director of the Comprehensive Epilepsy Center and Chief of the Epilepsy Division at the Department of Neurology of the University of Miami, Miller School of Medicine, and Dr. Heidi Marie Munger Clary, Associate Professor of Neurology, Epilepsy Fellowship Director and Director of Faculty Research Development at Wake Forest University School of Medicine.